|
|
|
|
Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis
|
|
|
|
|
|
|
|
نویسنده
|
cheng j. ,park d.e. ,berrios c. ,white e.a. ,arora r. ,yoon r. ,branigan t. ,xiao t. ,westerling t. ,federation a. ,zeid r. ,strober b. ,swanson s.k. ,florens l. ,bradner j.e. ,brown m. ,howley p.m. ,padi m. ,washburn m.p. ,decaprio j.a.
|
|
منبع
|
plos pathogens - 2017 - دوره : 13 - شماره : 10
|
|
چکیده
|
Merkel cell carcinoma (mcc) frequently contains integrated copies of merkel cell polyomavirus dna that express a truncated form of large t antigen (lt) and an intact small t antigen (st). while lt binds rb and inactivates its tumor suppressor function,it is less clear how st contributes to mcc tumorigenesis. here we show that st binds specifically to the myc homolog mycl (l-myc) and recruits it to the 15-component ep400 histone acetyltransferase and chromatin remodeling complex. we performed a large-scale immunoprecipitation for st and identified co-precipitating proteins by mass spectrometry. in addition to protein phosphatase 2a (pp2a) subunits,we identified mycl and its heterodimeric partner max plus the ep400 complex. immunoprecipitation for max and ep400 complex components confirmed their association with st. we determined that the st-mycl-ep400 complex binds together to specific gene promoters and activates their expression by integrating chromatin immunoprecipitation with sequencing (chip-seq) and rna-seq. mycl and ep400 were required for maintenance of cell viability and cooperated with st to promote gene expression in mcc cell lines. a genome-wide crispr-cas9 screen confirmed the requirement for mycl and ep400 in mcpyv-positive mcc cell lines. we demonstrate that st can activate gene expression in a ep400 and mycl dependent manner and this activity contributes to cellular transformation and generation of induced pluripotent stem cells. © 2017 cheng et al.
|
|
|
|
|
آدرس
|
department of medical oncology,dana-farber cancer institute,boston,ma,united states,department of medicine,brigham and women’s hospital,boston,ma,united states,department of medicine,harvard medical school,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,graduate school of arts and sciences,harvard university,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,department of microbiology and immunobiology,harvard medical school,boston,ma, United States, department of microbiology and immunobiology,harvard medical school,boston,ma,united states,department of otorhinolaryngology,university of pennsylvania perelman school of medicine,philadelphia,pa, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,national centre for biological sciences (ncbs),bangalore, India, department of medical oncology,dana-farber cancer institute,boston,ma,united states,graduate school of arts and sciences,harvard university,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,graduate school of arts and sciences,harvard university,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,center for functional cancer epigenetics,dana-farber cancer institute,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,department of medicine,brigham and women’s hospital,boston,ma,united states,department of medicine,harvard medical school,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,graduate school of arts and sciences,harvard university,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,graduate school of arts and sciences,harvard university,boston,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma, United States, stowers institute for medical research,kansas city,mo, United States, stowers institute for medical research,kansas city,mo, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,department of medicine,brigham and women’s hospital,boston,ma,united states,department of medicine,harvard medical school,boston,ma,united states,novartis institutes for biomedical research,cambridge,ma, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,department of medicine,brigham and women’s hospital,boston,ma,united states,department of medicine,harvard medical school,boston,ma,united states,center for functional cancer epigenetics,dana-farber cancer institute,boston,ma, United States, department of microbiology and immunobiology,harvard medical school,boston,ma, United States, department of medicine,harvard medical school,boston,ma,united states,department of biostatistics and computational biology,dana-farber cancer institute,boston,ma, United States, stowers institute for medical research,kansas city,mo,united states,department of pathology and laboratory medicine,university of kansas medical center,kansas city,ks, United States, department of medical oncology,dana-farber cancer institute,boston,ma,united states,department of medicine,brigham and women’s hospital,boston,ma,united states,department of medicine,harvard medical school,boston,ma, United States
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|